Clinical trials


Last updated: 2021 Sep 8
Total hit(s): 106
Select item(s)
Key Findings
Comments
(You can add your comments too!)
Original Article
(hover to see details)
The difference between CRP 1 and CRP 2 levels was significant (p=0.005) in the melatonin group (before and after receiving melatonin). The recovery percentage was higher in patients who received melatonin vs control group (85.7% VS 47.1%) .The percentage of symptom improvement was more in males than in females (62.5% VS 33.3%). Monitoring of cytokine,CRP levels and characterization of immune cells will provide a better picture about the impact of melatonin.
34418903
(Iran J Allergy Asthma Immunol)
PMID
34418903
Date of Publishing: 2021 Aug 7
Title A Pilot Study on Controlling Coronavirus Disease 2019 (COVID-19) Inflammation Using Melatonin Supplement
Author(s) nameAlizadeh Z, Keyhanian N et al.
Journal Iran J Allergy Asthma Immunol
Impact factor
1.17
Date of Entry 2021 Sep 8


Tocilizumab (TCZ) was used for the treatment of 46 critically ill COVID-19 patients and it do not show better survival compared to Dexamethasone. The need for ventilation cannot be avoided and gives no improvement from mortality. The need for mechanical ventilation is same between control and treatment group.
33893337
(Sci Rep)
PMID
33893337
Date of Publishing: 2021 Apr 23
Title Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab
Author(s) nameRashad A, Mousa S et al.
Journal Sci Rep
Impact factor
4.12
Citation count: 1
Date of Entry 2021 Aug 3


Dexamethasone was used for the treatment of 63 critically ill COVID-19 patients. It showed showed better survival of severe COVID patients compared to Tocilizumab. Dexamethasone gives better survival than Toclizumab and it cancels outs the need for ventilators.
33893337
(Sci Rep)
PMID
33893337
Date of Publishing: 2021 Apr 23
Title Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab
Author(s) nameRashad A, Mousa S et al.
Journal Sci Rep
Impact factor
4.12
Citation count: 1
Date of Entry 2021 Aug 3


No significant reduction in viral load was observed from baseline to day 15 among different treatment group patients (Lopinavir/Ritonavir, IFN-Ŗ-1a, Hydroxychloroquine, and control group ). Normalized SARS-CoV-2 viral loads were qualitatively and quantitatively assessed in Nasopharyngeal and lower respiratory specimens.
Pre-print (medRXiv)
Date of Publishing -
Title Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial
Author(s) name -
Date of Entry 2021 Jun 14


Among all treatment group patients, Lopinavir/ritonavir group patients experienced more serious adverse effects (52.8% in the lopinavir/ritonavir group vs. 38.5% in the control group; 54.2% in the lopinavir/ritonavir plus IFN-Ŗ-1a group vs. 38.5% in the control group). 44.1% of patients in the Hydroxychloroquine treated group had Serious adverse effects. 4 non-pulmonary-related deaths were found in two treatment groups (lopinavir/ritonavir group, n=1; lopinavir/ritonavir plus IFN-Ŗ-1a group, n=3).
Pre-print (medRXiv)
Date of Publishing -
Title Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial
Author(s) name -
Date of Entry 2021 Jun 14


No significant improvements were observed in clinical status (in terms of WHO 7-point ordinal scale) between different treatment groups (Lopinavir/Ritonavir, IFN-Ŗ-1a, Hydroxychloroquine) and control group patients on the 15th day and 29th day. The median age was 63 years,
the participants were mostly male (71.7%). The median time from symptom onset to randomization was 9 days.
The most frequent underlying conditions were obesity (28.7%), chronic cardiac disease (26.0%) and diabetes mellitus (22.0%). The remdesivir arm is continuing and currently enrolling patients. Thus, no clinical outcome for Remdesivir treatment is given.
Pre-print (medRXiv)
Date of Publishing -
Title Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial
Author(s) name -
Date of Entry 2021 Jun 14


The case study is of a 66-year-old man who experienced acute colic perforation after being treated with tocilizumab and corticosteroids for his COVID-19 diagnosis. The patient had a medical history of metabolic syndrome without any regular treatment.
32402416
(Cir Esp)
PMID
32402416
Date of Publishing: 2021 Feb
Title Intestinal perforation in patient with COVID-19 infection treated with tocilizumab and corticosteroids. Report of a clinical case
Author(s) nameGonz√°lvez Guardiola P, D√≠ez Ares J√Ā et al.
Journal Cir Esp
Impact factor
0.36
Citation count: 1


Ivermectin-treated group patients had a lower mortality rate compared to the control group patients. Mortality also was lower in the subgroup of Ivermectin-treated patients with severe pulmonary involvement. Ivermectin treatment was shown to be associated with lower mortality rate. However, more clinical trials are underway.
33065103
(Chest)
PMID
33065103
Date of Publishing: 2021 Jan
Title Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study
Author(s) nameRajter JC, Sherman MS et al.
Journal Chest
Impact factor
7.22
Citation count: 19


No patients in the fluvoxamine-treated group had clinical deterioration, whereas 8.3% of patients in the placebo group showed clinical deterioration.
33180097
(JAMA)
PMID
33180097
Date of Publishing: 2020 Dec 8
Title Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19
Author(s) nameLenze EJ, Mattar C et al.
Journal JAMA
Impact factor
14.78
Citation count: 6


Compared to the placebo group patients, the fluvoxamine-treated group patients showed less serious adverse effects.
33180097
(JAMA)
PMID
33180097
Date of Publishing: 2020 Dec 8
Title Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19
Author(s) nameLenze EJ, Mattar C et al.
Journal JAMA
Impact factor
14.78
Citation count: 6


A significant increase in Aminotransferase levels was observed in patients treated with Tocilizumab (TCZ), compared to Anakinra (ANA) treated group patients. Anakinra can be used to treat COVID-19 patients elevated aminotransferases and also useful for patients who do not respond to TCZ.
32843231
(J Autoimmun)
PMID
32843231
Date of Publishing: 2020 Dec
Title High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients
Author(s) nameIglesias-Julián E, López-Veloso M et al.
Journal J Autoimmun
Impact factor
7.32
Citation count: 3


Patients treated with Anakinra within 36 hours after the onset of acute hypoxemic respiratory failure showed better improvement (without mechanical ventilation). Randomized controlled trials are needed to determine the safety and efficacy of anakinra in patients with COVID19
32602262
(Arthritis Rheumatol)
PMID
32602262
Date of Publishing: 2020 Dec
Title Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID19: A Case Series
Author(s) nameNavarro-Mill√°n I, Sattui SE et al.
Journal Arthritis Rheumatol
Impact factor
7.34
Citation count: 11


55.6% and 88.9% of patients showed positive outcomes when treated with Anakinra (ANK) and Tocilizumab (TCZ), respectively. Two patients who did not improve by TCZ drug treatment were treated successfully by ANK treatment. ANK is a potential alternative drug for treating patients who are not responding to TCZ.
32843231
(J Autoimmun)
PMID
32843231
Date of Publishing: 2020 Dec
Title High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients
Author(s) nameIglesias-Julián E, López-Veloso M et al.
Journal J Autoimmun
Impact factor
7.32
Citation count: 3


HCQ did not significantly reduce the viral load in patients. No differences in the viral load reduction between the two groups of patients were observed (HCQ and control group). Samples were tested for the detection of N1 and N2 targets (nucleoprotein gene) of the SARS-CoV-2. Samples with Ct values <40 were considered positive
33111169
(Braz J Microbiol)
PMID
33111169
Date of Publishing: 2020 Dec
Title No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19
Author(s) nameFaíco-Filho KS, Conte DD et al.
Journal Braz J Microbiol
Impact factor
1.67
Citation count: 2


Several common serious adverse effects were observed between two groups of patients (IFX-1 and control). In the IFX-1 group, 23 serious adverse effects occurred in 9 out of 15 patients. In the control group, 19 adverse effects occurred in 7 out of 15 patients.
33015643
(Lancet Rheumatol)
PMID
33015643
Date of Publishing: 2020 Dec
Title Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Author(s) nameVlaar APJ, de Bruin S et al.
Journal Lancet Rheumatol
Impact factor
<3years
Citation count: 8


Clinical outcomes in patients treated with IFX-1 (vilobelimab) showed a positive (but not significant) difference compared to the control group. The mortality by 28 days was 13% for the IFX-1 group and 27% for the control group. IFX-1 resulted in C5a inhibition and appeared to be safe and promising in treating severe COVID-19 patients. The Clinical results of the trial appeared to be effective and safe and thus recommended for the phase 3 trial.
33015643
(Lancet Rheumatol)
PMID
33015643
Date of Publishing: 2020 Dec
Title Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Author(s) nameVlaar APJ, de Bruin S et al.
Journal Lancet Rheumatol
Impact factor
<3years
Citation count: 8


Patients treated with the Remdesivir had better clinical improvement and less mortality than patients in the placebo group. The benefits of remdesivir was more when administered earlier in the illness. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262788/table/t3/)
32445440
(N Engl J Med)
PMID
32445440
Date of Publishing: 2020 Nov 5
Title Remdesivir for the Treatment of Covid-19 Final Report
Author(s) nameBeigel JH, Tomashek KM et al.
Journal N Engl J Med
Impact factor
37.91
Citation count: 690


Adverse effects were similar between two groups (Remdesivir and placebo) of patients. Serious adverse effects were reported in 131 patients in the Remdesivir group and 163 patients in the placebo group.
32445440
(N Engl J Med)
PMID
32445440
Date of Publishing: 2020 Nov 5
Title Remdesivir for the Treatment of Covid-19 Final Report
Author(s) nameBeigel JH, Tomashek KM et al.
Journal N Engl J Med
Impact factor
37.91
Citation count: 690


16 out of 17 COVID-19 patients with profound B-cell lymphopenia showed an effective improvement (in clinical symptoms and biological parameters) when treated with the passive transfer of COVID-19-neutralizing antibodies through CPT. Convalescent plasma with antiSARS-CoV-2 antibodies is a better approach for treating patients with prolonged COVID-19 symptoms who have impaired adaptive humoral response.
32959052
(Blood)
PMID
32959052
Date of Publishing: 2020 Nov 12
Title Convalescent plasma therapy for B-celldepleted patients with protracted COVID-19
Author(s) nameHueso T, Pouderoux C et al.
Journal Blood
Impact factor
10.66
Citation count: 9


A pregnant woman with severe COVID-19 was treated successfully with Tocilizumab and Remdesivir with better clinical improvement. Chest X-ray showed bilateral patchy infiltrates
32618794
(Obstet Gynecol)
PMID
32618794
Date of Publishing: 2020 Nov
Title Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19)
Author(s) nameNaqvi M, Zakowski P et al.
Journal Obstet Gynecol
Impact factor
3.78
Citation count: 5


Compared to the control group patients (not-transfused), patients transfused within 72 hours of hospital admission had decreased mortality within 28 days. And a significant reduction in mortality was observed in patients transfused with high anti-RBD IgG titer COVID-19 convalescent plasma within 72 hours of admission.
32795424
(Am J Pathol)
PMID
32795424
Date of Publishing: 2020 Nov
Title Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality
Author(s) nameSalazar E, Christensen PA et al.
Journal Am J Pathol
Impact factor
3.71
Citation count: 15


Compared to the HCQ alone or no treatment group patients, the combination-treated group patients (HCQ+ azithromycin) had a lower mortality rate. Age, mechanical ventilation/continuous positive airway pressure, and C reactive protein above the median were directly associated with death.
32926573
(Clin Transl Sci)
PMID
32926573
Date of Publishing: 2020 Nov
Title Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19
Author(s) nameLauriola M, Pani A et al.
Journal Clin Transl Sci
Impact factor
3.75
Citation count: 5


This case study involves a 68-year-old SARS-CoV-2 positive female patient with a medical history of coronary artery disease, was treated with Remedesivir. The patient experienced associated acute liver failure, which improved with the treatment of acetylcysteine. The patient had a medical history of hypertension, diabetes mellitus, hyperlipidemia, and coronary artery disease (CAD)
33006138
(Pharmacotherapy)
PMID
33006138
Date of Publishing: 2020 Nov
Title Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series
Author(s) name Carothers C, Birrer K, Vo M.
Journal Pharmacotherapy
Impact factor
3.17
Citation count: 1


The patient treated with Remedesivir experienced acute liver failure which improved with the treatment of acetylcysteine The patient had a medical history of hypertension, diabetes mellitus, hyperlipidemia, and coronary artery disease (CAD)
33006138
(Pharmacotherapy)
PMID
33006138
Date of Publishing: 2020 Nov
Title Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series
Author(s) name Carothers C, Birrer K, Vo M.
Journal Pharmacotherapy
Impact factor
3.17
Citation count: 1


The patient treated with Remedesivir experienced acute liver failure which improved with the treatment of acetylcysteine The patient had a medical history of hypertension, diabetes mellitus, and hyperlipidemia.
33006138
(Pharmacotherapy)
PMID
33006138
Date of Publishing: 2020 Nov
Title Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series
Author(s) name Carothers C, Birrer K, Vo M.
Journal Pharmacotherapy
Impact factor
3.17
Citation count: 1